Brendan Manning, Ph.D.

Brendan Manning, Ph.D.

Professor and Acting Chair, Department of Molecular Metabolism (Harvard T.H. Chan School of Public Health
Affiliate Member of Cell Biology (HMS)

Brendan Manning, Ph.D. is a Professor and Acting Chair in the Department of Molecular Metabolism at the Harvard T.H. Chan School of Public Health. He received his PhD from Yale University in 2000 and was a postdoctoral fellow at Harvard Medical School. In 2004, Dr. Manning became the first faculty member hired in the then newly established Department of Genetics and Complex Diseases (later changed to Molecular Metabolism) at Harvard-Chan. Dr. Manning was an inaugural recipient of the National Cancer Institute’s Outstanding Investigator Award. 

Research in the Manning lab is defining the molecular interface between cellular signaling networks and metabolic networks, as it relates to both normal physiology and diseases with metabolic dysregulation as a key feature, including cancer, diabetes, and aging-related diseases. Research efforts are focused in part on defining the regulatory mechanisms and functions of a signaling network converging on the tuberous sclerosis complex (TSC) protein complex and the mammalian target of rapamycin (mTOR), which relay an array of extracellular and intracellular growth signals to control the balance between anabolic and catabolic metabolism in cells, tissues, and tumors.

665 Huntington Ave

SPH2-117

Boston, MA 02115

mTOR links oncogenic signaling to tumor cell metabolism.
Authors: Authors: Yecies JL, Manning BD.
J Mol Med (Berl)
View full abstract on Pubmed
mTOR couples cellular nutrient sensing to organismal metabolic homeostasis.
Authors: Authors: Howell JJ, Manning BD.
Trends Endocrinol Metab
View full abstract on Pubmed
Insulin signaling: inositol phosphates get into the Akt.
Authors: Authors: Manning BD.
Cell
View full abstract on Pubmed
Activation of a metabolic gene regulatory network downstream of mTOR complex 1.
Authors: Authors: Düvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM, Clish CB, Murphy LO, Manning BD.
Mol Cell
View full abstract on Pubmed
Chewing the fat on tumor cell metabolism.
Authors: Authors: Yecies JL, Manning BD.
Cell
View full abstract on Pubmed
Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1.
Authors: Authors: Dibble CC, Asara JM, Manning BD.
Mol Cell Biol
View full abstract on Pubmed
A molecular link between AKT regulation and chemotherapeutic response.
Authors: Authors: Dibble CC, Manning BD.
Cancer Cell
View full abstract on Pubmed
Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
Authors: Authors: Huang J, Wu S, Wu CL, Manning BD.
Cancer Res
View full abstract on Pubmed
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
Authors: Authors: James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, Gusella JF, Ramesh V.
Mol Cell Biol
View full abstract on Pubmed
Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway.
Authors: Authors: Zhang HH, Huang J, Düvel K, Boback B, Wu S, Squillace RM, Wu CL, Manning BD.
PLoS One
View full abstract on Pubmed